Related coverage linked through entity extraction aliases.
Mar 02, 2026
Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to Sanofi's rilzabrutinib for IgG4-related disease, marking the third global orphan designation for this indication based on positive phase 2 study data.
Mar 02, 2026
Regeneron has consistently increased revenue over 35 years with blockbuster products like Dupixent and Eylea HD, while maintaining over a dozen phase 3 clinical trial candidates across multiple therapeutic areas.
Mar 01, 2026
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Feb 28, 2026
Sanofi receives FDA approval for Dupixent to treat allergic fungal rhinosinusitis and gains European endorsement for Acoziborole Winthrop as a sleeping sickness treatment, which will be donated to WHO.
Feb 25, 2026
The global pharmaceutical market reached nearly $1.7 trillion in value, with Johnson & Johnson leading prescription sales at approximately $55.8 billion while Merck & Co. topped research and development investment at $17.8 billion.
Feb 26, 2026
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
Feb 24, 2026
The FDA reversed its decision to reject Moderna's mRNA influenza vaccine application, accepting it for review one week after an initial refusal-to-file that reportedly involved senior leaders overruling staff advice.
Feb 13, 2026
Major pharmaceutical companies are highlighting their drug pipelines to offset upcoming patent losses, while Moderna confronts FDA rejection of its flu vaccine. The industry faces significant revenue challenges from patent cliffs in 2026.
Feb 19, 2026
A comprehensive report on encephalitis clinical trials has been added to ResearchAndMarkets.com's offering, providing data on trial numbers, enrollment trends, and geographic distribution across G7 and E7 countries.
Feb 18, 2026
Trellus Health announced a six-month extension of its contract with Johnson & Johnson to provide the Trellus Elevate platform for inflammatory bowel disease patients, driven by strong engagement and satisfaction metrics achieved during the pilot phase.
Feb 18, 2026
The U.S. orphan drug market is projected to exceed $200 billion by 2031, driven by innovation in oncology and genetic disorders. More than 1,400 FDA-designated orphan drugs are in development or marketed, with over 800 currently in clinical trials.
Feb 17, 2026
Teva and Sanofi reported positive 44-week data from the RELIEVE UCCD long-term extension study of duvakitug, showing durable efficacy in ulcerative colitis and Crohn's disease patients.
Feb 16, 2026
The global antibodies market is projected to reach $667.8 billion by 2032 with a 12.9% CAGR, while high throughput antibody production services are expected to grow at 11.2% CAGR through 2033, driven by biopharmaceutical development and monoclonal antibody therapeutics demand.
Feb 15, 2026
BioAsia 2026 in Hyderabad attracted over 4,000 delegates and 500 companies, featuring AI-driven drug discovery platforms and showcasing Indian biotech innovations including BioVaram's regenerative medicine breakthrough.
Feb 13, 2026
Researchers at Icahn School of Medicine at Mount Sinai found that major depressive disorder shares key immune abnormalities with atopic dermatitis, particularly Th2 pathway activation. The team plans to test dupilumab in a clinical trial for depression.
Feb 13, 2026
Sanofi replaced CEO Paul Hudson with Belén Garijo from Merck KGaA after a stalled turnaround. The company faces pressure to develop drugs to replace blockbuster Dupixent and navigate U.S. vaccine skepticism.
Feb 13, 2026
The FDA mandated febrile seizure warnings for flu vaccines and rejected Moderna's mRNA flu vaccine application, with a political appointee overruling agency staff despite no safety concerns identified.
